MILREM-ROBOTICS
30.6.2021 09:02:13 CEST | Business Wire | Press release
The consortium behind iMUGS, a 32,6 MEUR project with the aim of developing the European standard unmanned ground system (UGS), demonstrated the results of the first phase of the project – deploying unmanned systems to the battlefield and teaming them with manned units and vehicles. The demonstration was spearheaded by the coordinator of the consortium, Europe’s leading developer of robotics and autonomous systems Milrem Robotics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005046/en/
During iMUGS (integrated Modular Unmanned Ground System) a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems will be developed to standardize a European wide ecosystem for aerial and ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.
The system will utilize an existing unmanned ground vehicle – Milrem Robotics’ THeMIS – and a specific list of payloads.
"The main objective of the iMUGS project is to integrate robotic systems with existing manned technology into European defence forces adding a new capability that will overmatch our adversaries’ abilities," said Kuldar Väärsi, CEO of Milrem Robotics. He noted that iMUGS will contribute to the strategic autonomy of the European Union and strengthen the cooperation between the member states.
During the first demonstration consortium partners showcased how the THeMIS can be deployed onto the battlefield using common Armoured Personnel Carriers (APC) and teamed with unmanned aerial systems. Specific technology used were the Boxer APC by Krauss-Maffei Wegmann (KMW) and a tethered drone by Acecore Technologies. A multirotor drone by Atlas Dynamics was also part of the scenario.
Altogether two scenarios were played out in cooperation with the Estonian Defence Forces.
In the first scenario the THeMIS integrated with Acecore’s tethered drone was operated Beyond the Line of Sight (BLOS) by the soldiers and used to detect and target an enemy position. After determining the target indirect fire was ordered and after-action review performed using the drone footage.
The purpose of the second scenario was to retrieve a casualty from a crashed vehicle and afterwards retrieve the vehicle. Both actions were performed with the THeMIS UGV while the Boxer towed the UGV into the mission area and Atlas’ drone provided overwatch and situational awareness.
“The demonstration confirmed that we have the interaction between manned and unmanned systems, as well as the interaction of hardware and software, under control,” said Thomas Reining, iMUGS Project Manager in Krauss-Maffei Wegmann.
The requirements for the standardized UGS have been set by seven EU member states: Estonia, the leader of the project, and Belgium, Finland, France, Germany, Latvia, and Spain.
“All of the participating nations have shown great interest in contributing to the development of the European UGS,” said Martin Jõesaar, iMUGS project officer in the Estonian Centre for Defence Investments. “The countries understand that they have to grow with the industry to integrate this kind of new technology rapidly and guide the industry towards the best solutions.”
iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Talgen Cybersecurity, Safran Electronics & Defense, NEXTER Systems, Krauss-Maffei Wegmann, Diehl Defence, Bittium, Insta DefSec, (Un)Manned, dotOcean, Latvijas Mobilais Telefons, GMV Aerospace and Defence, and Royal Military Academy of Belgium.
Watch the Demo 1 Scenario 1 here - https://youtu.be/wAQHPdmm48M
Watch the Demo 1 Scenario 2 here - https://youtu.be/2vobuDOcfDA
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom